Harpreet Singh, Immatics CEO (Credit: Allogeneic Cell Therapies Summit)
Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists
Just a few weeks after offering a positive readout on its first early clinical-stage offering, the transatlantic biotech Immatics is back with news that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
